Department of Hematology-Oncology, East Tennessee Children's Hospital, Knoxville, Tennessee, USA.
Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Pediatr Dermatol. 2024 Nov-Dec;41(6):1246-1247. doi: 10.1111/pde.15710. Epub 2024 Sep 3.
An 11-year-old female with neurofibromatosis type 1 (NF-1) and history of optic glioma presented with a progressive cutaneous plexiform neurofibroma of the breast. The lesion was treated with topical application of a mitogen-activated protein kinase inhibitor, trametinib, resulting in stable, non-progression cutaneous plexiform neurofibroma for greater than 2 years. This case demonstrates the potential application of topical trametinib for NF1-associated superficial cutaneous plexiform neurofibroma without the toxicities associated with systemic treatment.
一位 11 岁的女性，患有神经纤维瘤病 1 型（NF-1）和视神经胶质瘤病史，现患有进行性乳房丛状神经纤维瘤。该病变采用丝裂原活化蛋白激酶抑制剂曲美替尼（trametinib）进行局部治疗，导致丛状神经纤维瘤稳定且无进展超过 2 年。该病例表明，局部应用曲美替尼治疗 NF1 相关的浅表丛状神经纤维瘤具有潜在的应用价值，且没有与全身治疗相关的毒性。
